Search

Your search keyword '"Chong, Dawn Qingqing"' showing total 17 results
Start Over Author "Chong, Dawn Qingqing"
17 results on '"Chong, Dawn Qingqing"'

2. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer

Author

Joanito, Ignasius, Wirapati, Pratyaksha, Zhao, Nancy, Nawaz, Zahid, Yeo, Grace, Lee, Fiona, Eng, Christine L. P., Macalinao, Dominique Camat, Kahraman, Merve, Srinivasan, Harini, Lakshmanan, Vairavan, Verbandt, Sara, Tsantoulis, Petros, Gunn, Nicole, Venkatesh, Prasanna Nori, Poh, Zhong Wee, Nahar, Rahul, Oh, Hsueh Ling Janice, Loo, Jia Min, Chia, Shumei, Cheow, Lih Feng, Cheruba, Elsie, Wong, Michael Thomas, Kua, Lindsay, Chua, Clarinda, Nguyen, Andy, Golovan, Justin, Gan, Anna, Lim, Wan-Jun, Guo, Yu Amanda, Yap, Choon Kong, Tay, Brenda, Hong, Yourae, Chong, Dawn Qingqing, Chok, Aik-Yong, Park, Woong-Yang, Han, Shuting, Chang, Mei Huan, Seow-En, Isaac, Fu, Cherylin, Mathew, Ronnie, Toh, Ee-Lin, Hong, Lewis Z., Skanderup, Anders Jacobsen, DasGupta, Ramanuj, Ong, Chin-Ann Johnny, Lim, Kiat Hon, Tan, Emile K. W., Koo, Si-Lin, Leow, Wei Qiang, Tejpar, Sabine, Prabhakar, Shyam, and Tan, Iain Beehuat

Published
2022
Full Text
View/download PDF

8. Heat selection enables highly scalable methylome profiling in cell-free DNA for noninvasive monitoring of cancer patients

Author

Cheruba, Elsie, primary, Viswanathan, Ramya, additional, Wong, Pui-Mun, additional, Womersley, Howard John, additional, Han, Shuting, additional, Tay, Brenda, additional, Lau, Yiting, additional, Gan, Anna, additional, Poon, Polly S. Y., additional, Skanderup, Anders, additional, Ng, Sarah B., additional, Chok, Aik Yong, additional, Chong, Dawn Qingqing, additional, Tan, Iain Beehuat, additional, and Cheow, Lih Feng, additional

Published
2022
Full Text
View/download PDF

14. What is the value of third‐line chemotherapy in advanced gastroesophageal cancer? A 5‐year retrospective analysis at a single center

Author

Lam, Justina Yick Ching, primary, Choo, Su Pin, additional, Tai, David Wai‐Meng, additional, Tan, Iain Bee Huat, additional, Tham, Chee Kian, additional, Koo, Wen Hsin, additional, Ong, Simon Yew Kuang, additional, Ang, Soo Fan, additional, Chua, Clarinda Wei Ling, additional, Chong, Dawn Qingqing, additional, Teo, Patrick Tze Hern, additional, Lee, Christabel Jing Zhi, additional, Ee, Samuel Cheng En, additional, and Ng, Matthew Chau Hsien, additional

Published
2019
Full Text
View/download PDF

15. What is the value of third‐line chemotherapy in advanced gastroesophageal cancer? A 5‐year retrospective analysis at a single center.

Author

Lam, Justina Yick Ching, Choo, Su Pin, Tai, David Wai‐Meng, Tan, Iain Bee Huat, Tham, Chee Kian, Koo, Wen Hsin, Ong, Simon Yew Kuang, Ang, Soo Fan, Chua, Clarinda Wei Ling, Chong, Dawn Qingqing, Teo, Patrick Tze Hern, Lee, Christabel Jing Zhi, Ee, Samuel Cheng En, and Ng, Matthew Chau Hsien

Subjects
ESOPHAGEAL cancer, CANCER chemotherapy, RETROSPECTIVE studies, STOMACH tumors, CANCER, METASTASIS
Abstract

Aim: The survival benefit of using a non‐cross resistant second‐line chemotherapy in the third‐line setting in metastatic gastroesophageal cancer is unproven. We evaluated the utility of third‐line chemotherapy in patients treated at a single institution. Methods: Between 2010 and 2014, efficacy and toxicity data of patients who received three or more lines of systemic therapies for metastatic gastroesophageal adenocarcinoma at the National Cancer Centre Singapore was retrospectively analyzed. Results: Thirty‐two (6%) patients received three or more lines of chemotherapy. The median age and ECOG performance status were 59 years (36–82) and 1 (0–2), respectively. Majority of patients (88%) had tumor located in the stomach and 13 patients (41%) had diffuse histology or poorly cohesive or signet ring cells. Four (12%) patients had HER2‐positive disease. Prior therapy was platinum (100%), fluoropyrimidine (97%), taxane (63%), irinotecan (28%), anthracycline (13%) and ramucirumab (3%). Third‐line therapy consisted of 24 (75%) monotherapy, 6 (19%) doublet, 1 (3%) triplet chemotherapy and 1 (3%) clinical trial. Monotherapy irinotecan (44%) was most common, followed by docetaxel (19%) and paclitaxel (9%). Of 22 patients evaluable for response, there was 1 (5%) partial response, 9 (41%) stable disease. Median overall survival was 18.3 weeks (4.3–65.1). Of 30 patients evaluable for toxicities, 17 (57%) experienced at least one grade 3 or 4 toxicities. Conclusion: The benefit of using non‐cross resistant second‐line regimens as third‐line chemotherapy was small with moderate toxicity. Newer agents such as nivolumab or TAS‐102 or clinical trial may be preferred. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. A phase Ib proof-of-concept study of LBH589 (LBH) and everolimus (EVE) in advanced solid tumors enriched for Epstein-Barr virus (EBV)-related cancers.

Author

Tan, Daniel Shao-Weng, primary, Ng, Quan Sing, additional, Chong, Dawn Qingqing, additional, Lee, Guek Eng, additional, Tan, Thuan Tong, additional, Chau, Noan Minh, additional, Ang, Mei-Kim, additional, Zhong, Liz, additional, Chowbay, Balram, additional, Connolly, John, additional, Tan, Eng-Huat, additional, and Lim, Wan-Teck, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results